author-photo

Aude Espinasse

Institute of Cancer Research

2

Papers

235

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (29)
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (206)